CN100451644C - Method for detecting quality of blood fat recovery capsule - Google Patents
Method for detecting quality of blood fat recovery capsule Download PDFInfo
- Publication number
- CN100451644C CN100451644C CNB2006101458385A CN200610145838A CN100451644C CN 100451644 C CN100451644 C CN 100451644C CN B2006101458385 A CNB2006101458385 A CN B2006101458385A CN 200610145838 A CN200610145838 A CN 200610145838A CN 100451644 C CN100451644 C CN 100451644C
- Authority
- CN
- China
- Prior art keywords
- peak
- peaks
- blood fat
- mobile phase
- recovery capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The method includes following steps: using octadecylsilane chemically bonded silica as filler; using acetonitrile as mobile phase A, and 0.05% phosphoric acid as mobile phase B to carry out gradient elution; under condition of detection wavelength as 256nm, column temperature as room temperature, velocity of flow as 1.0ml/min, weighing up reference substance 1mg of rovastatin in 5ml volumetric flask, and adding constant volume of acetonitrile to scale so as to obtain solution of reference substance; taking content substance 0.3g of Xuezhikang capsule, adding acetonitrile 2ml, carrying out supersound extraction for 10-20min, using 0.45 micros microporous membrane to carry out filtering operation so as to obtain sample solution; mensuration according to high performance liquid chromatography; fingerprint of sample solution should possess good comparability to the referenced fingerprint, degree of similarity larger than 0.90. Features are: simple operation and good reproducibility.
Description
Technical field
The present invention relates to a kind of quality determining method of Chinese medicinal capsule agent, particularly the finger print quality detecting method of blood fat recovery capsule.
Background technology
Blood fat recovery capsule is to be raw material with the Chinese medicine red colouring agent for food, also used as a Chinese medicine, the product with effects such as dehumidifying is eliminated the phlegm, promoting blood circulation and removing blood stasis, reinforcings spleen to promote digestion through developing according to No. 200510134728.4 patent technology.Clinically also be used for the treatment of the cardiovascular and cerebrovascular disease that hyperlipemia and artery sclerosis cause.Along with the raising of blood fat recovery capsule popularity, some fake productss have appearred on the market, these product serious harms people's life security, and existing quality standard is an index to measure single component Lovastatin content only, difficult difference fake products.In addition, single assay index also can't reflect comprehensively and control the quality of the pharmaceutical preparations, for improving drug standard, must set up the medicine finger print quality detecting method.
Summary of the invention
The object of the present invention is to provide a kind of quality determining method of blood fat recovery capsule.
The present invention seeks to be achieved through the following technical solutions.
The quality determining method of blood fat recovery capsule of the present invention comprises the quality determining method of finger-print, and this method comprises the steps:
According to high effective liquid chromatography for measuring, an appendix VI of Pharmacopoeia of the People's Republic of China D;
Chromatographic condition and system suitability test are filling agent with octadecylsilane chemically bonded silica; With the acetonitrile is mobile phase A, is that Mobile phase B is carried out gradient elution with 0.05% phosphoric acid; The detection wavelength is 256nm; Column temperature is a room temperature; Flow velocity is 1.0ml/min; The preparation of object of reference solution, precision take by weighing Lovastatin reference substance 1mg in the 5ml volumetric flask, add acetonitrile and are settled to scale, promptly; Blood fat recovery capsule content 0.3g is got in the preparation of need testing solution, adds acetonitrile 2ml, and ultrasonic Extraction 10～20min filters with 0.45 μ m miillpore filter, is need testing solution; Determination method with need testing solution 10 μ l, is injected high performance liquid chromatograph, record 55min chromatogram.The test product finger-print should have good similarity with reference fingerprint, similarity＞0.90 (calculate with " the chromatographic fingerprints of Chinese materia medica similarity evaluation B of system version ", Chinese Pharmacopoeia Commission issues);
The eluent gradient elution program is in the said determination method: the mobile phase A volume ratio rose to 84% by 25% linearity in 0～45 minute, and the Mobile phase B volume ratio drops to 16% by 75% linearity; The mobile phase A volume ratio dropped to 25% by 84% linearity in 45～55 minutes, and the Mobile phase B volume ratio rises to 75% by 16% linearity; 55～65 minutes mobile phase A volume ratios remain 25%, the Mobile phase B volume ratio remains 75%.Wherein the finger-print deadline is 55 minutes, and 55～65 minutes is the system balancing time.
The preferred Apollo C18 of chromatographic column in said determination method post, specification are 250 * 4.6mm, 5 μ m.Said determination method medium wavelength detecting device is the DAD detecting device.
The blood fat recovery capsule finger-print can have 15 total fingerprint peakses, is Lovastatin S with reference to the peak;
The relative retention time of 15 total fingerprint peakses is respectively: No. 1 the peak is 0.315 ± 0.002, No. 2 the peak is 0.328 ± 0.002, No. 3 the peak is 0.378 ± 0.002, No. 4 the peak is 0.397 ± 0.006, No. 5 the peak is 0.447 ± 0.001, No. 6 the peak is 0.566 ± 0.001, No. 7 peaks are that 0.593 ± 0.001, No. 8 peaks are that 0.683 ± 0.003, No. 9 peaks are 0.784 ± 0.001, No. 10 the peak is 0.834 ± 0.001, No. 11 peaks are that 0.895 ± 0.000, No. 12 peaks are that 0.920 ± 0.000, No. 13 peaks are 0.952 ± 0.000, No. 14 peaks are that the S peak is that 1.000 ± 0.000, No. 15 peaks are 1.225 ± 0.001;
The relative peak area ratio of 15 total fingerprint peakses is respectively: No. 1 peak 0.191 ± 0.028, No. 2 peaks 0.031 ± 0.005, No. 3 peaks 0.1269 ± 0.031, No. 4 peaks 0.061 ± 0.027, No. 5 peaks 0.307 ± 0.047, No. 6 peaks 0.067 ± 0.012,0.032 ± 0.013, No. 9 peaks 0.073 ± 0.008,0.132 ± 0.021, No. 8 peaks, No. 7 peaks, No. 10 peaks 0.073 ± 0.015,0.083 ± 0.010, No. 13 peaks 0.039 ± 0.010,0.115 ± 0.030, No. 12 peaks, No. 11 peaks, No. 14 peaks are 1.000 ± 0.000, No. 15 peaks 0.119 ± 0.036, S peak.
Wherein, the preferred relative retention time of 15 total fingerprint peakses is respectively: No. 1 peak is that 0.315, No. 2 peak is 0.328, No. 3 peaks are that 0.378, No. 4 peak is that 0.3968, No. 5 peak is 0.447, No. 6 peaks are that 0.566, No. 7 peak is that 0.593, No. 8 peak is 0.683, No. 9 peaks are that 0.784, No. 10 peak is that 0.834, No. 11 peak is 0.895, No. 12 the peak is 0.920, No. 13 peaks are that 0.952, No. 14 peak is that the S peak is that 1.000, No. 15 peaks are 1.225;
The preferred relative peak area ratio of 15 total fingerprint peakses is respectively: 0.031, No. 3 peak 0.126,0.191, No. 2 peak, No. 1 peak, 0.307, No. 6 peak 0.067,0.061, No. 5 peak, No. 4 peaks, 0.032, No. 9 peak 0.073,0.132, No. 8 peak, No. 7 peaks, No. 10 peaks 0.073,0.083, No. 13 peak 0.039,0.115, No. 12 peak, No. 11 peaks, No. 14 peaks are 1.000, No. 15 peaks 0.119, S peak.
The blood fat recovery capsule finger-print can also select for use 9 total peaks as finger-print in above-mentioned 15 total fingerprint peakses, is Lovastatin S with reference to the peak;
The relative retention time of 9 total fingerprint peakses is respectively: No. 1 the peak is 0.315 ± 0.002, No. 2 the peak is 0.328 ± 0.002, No. 3 the peak is 0.378 ± 0.002, No. 4 the peak is 0.397 ± 0.006, No. 5 peaks are that 0.447 ± 0.001, No. 6 peaks are that 0.566 ± 0.001, No. 7 peaks are 0.593 ± 0.001, No. 14 peaks are that the S peak is that 1.000 ± 0.000, No. 15 peaks are 1.225 ± 0.001;
The relative peak area ratio of 9 total fingerprint peakses is respectively: No. 1 peak 0.191 ± 0.028, No. 2 peaks 0.031 ± 0.005, No. 3 peaks 0.1269 ± 0.031, No. 4 peaks 0.061 ± 0.027,0.067 ± 0.012, No. 7 peaks 0.132 ± 0.021,0.307 ± 0.047, No. 6 peaks, No. 5 peaks, No. 14 peaks are 1.000 ± 0.000, No. 15 peaks 0.119 ± 0.036, S peak.
Wherein, the preferred relative retention time of 9 total fingerprint peakses is respectively: No. 1 peak is that 0.315, No. 2 peak is that 0.328, No. 3 peak is 0.378, No. 4 peaks are that 0.3968, No. 5 peak is that 0.447, No. 6 peak is 0.566, No. 7 peaks are that 0.593, No. 14 peak is that the S peak is that 1.000, No. 15 peaks are 1.225;
The preferred relative peak area ratio of 9 total fingerprint peakses is respectively: 0.132, No. 14 peak, 0.067, No. 7 peak, 0.307, No. 6 peak, 0.061, No. 5 peak, 0.126, No. 4 peak, 0.031, No. 3 peak, 0.191, No. 2 peak, No. 1 peak is 1.000, No. 15 peaks 0.119, S peak.
After adopting fingerprint atlas detection method of the present invention that blood fat recovery capsule is carried out quality control, improved the quality control standard of blood fat recovery capsule, guaranteed the effect of this medicine, and finger print measuring method of the present invention operates and has easy, high repeatability and other advantages.
Description of drawings:
Fig. 1: blood fat recovery capsule of the present invention (15 peak) finger-print
Fig. 2: flow phase system is the blood fat recovery capsule finger-print of methyl alcohol-0.05% phosphoric acid
Fig. 3: flow phase system is the blood fat recovery capsule finger-print of methyl alcohol-acetonitrile-0.05% phosphoric acid
Fig. 4: flow phase system is the blood fat recovery capsule finger-print of acetonitrile-water
Fig. 5: flow phase system is the blood fat recovery capsule finger-print of acetonitrile-0.1% phosphoric acid
Following experimental example and embodiment are used to further specify but are not limited to the present invention.
The research of experimental example blood fat recovery capsule finger print quality detecting method
1. the preparation of need testing solution
Blood fat recovery capsule is 75% ethanol extract of red colouring agent for food, also used as a Chinese medicine, and relatively methyl alcohol, 75% ethanol, acetonitrile extract solvent for three kinds, and the finger-print general picture of three's extract is identical, but the acetonitrile extract is of light color a lot, t in the chromatogram
RThe pigment composition stripping of＜10min is less relatively.Three t
RThe total fingerprint peaks of＞10min is similar, pollutes for reducing post, prolongs column life, adopts acetonitrile as extracting solvent.
Compare ultrasonic Extraction and heating and refluxing extraction, easy, the favorable reproducibility of former approach.
The chromatogram that compares ultrasonic Extraction 5min, 10min, 20min, behind the 10min, each material extraction ratio changes not quite in the finger-print, so extraction time is defined as 10min.
Adopt HP-20 and D-101 macroporous absorbent resin to dispel pigment and disturb, effect is undesirable, poor reproducibility; It is better that silica gel, aluminium oxide are dispeled the pigment effect, but the loss of total peak is more, will not adopt.
2. the preparation of object of reference solution
Lovastatin is the hypolipidemic activity composition of blood fat recovery capsule, and the big and stable in properties of content is suitable as object of reference.
3. detection method
(1) selection of chromatographic column
Under the same terms, compared Apollo, YMC, three kinds of C18 chromatographic columns of Kromasil (250 * 4.6mm, 5 μ m), the three has good separation to sample is even, Apollo post longer service life, cost performance is higher.
(2) selection of moving phase
Having screened 5 kinds altogether forms and the different flow phase system of gradient: methyl alcohol-0.05% phosphoric acid (seeing accompanying drawing 2), methyl alcohol-acetonitrile-0.05% phosphoric acid (seeing accompanying drawing 3), acetonitrile-water (seeing accompanying drawing 4), acetonitrile-0.05% phosphoric acid (seeing accompanying drawing 1), acetonitrile-0.1% phosphoric acid (seeing accompanying drawing 5).The result shows that by above-mentioned condition gradient elution, the collection of illustrative plates baseline is steady with acetonitrile-0.05% phosphoric acid, and each chromatographic peak separates good, and the finger-print deadline is moderate.
(3) selection of detection wavelength
There is the material of uv absorption to be mainly pigment, flavones, his spit of fland in the blood fat recovery capsule.The DAD detecting device is adopted in this test, and through comparing under 256nm, the collection of illustrative plates baseline is steady, and each chromatographic peak degree of separation is good, and absorbance log is moderate, therefore selects 256nm as detecting wavelength.
(4) methodological study
1. blood fat recovery capsule finger-print precision test
Get same need testing solution,, the results are shown in Table 1 by above-mentioned chromatographic condition continuous sample introduction 5 pins.Each finger-print and reference fingerprint be similarity＞0.90 relatively;
Table 1 blood fat recovery capsule finger-print precision is investigated the result
2. blood fat recovery capsule finger-print stability test
Get same need testing solution, by above-mentioned chromatographic condition respectively at 0,8,16,24, the 36h sample introduction, the results are shown in Table 2.Each finger-print and reference fingerprint be similarity＞0.90 relatively, and the result shows that need testing solution is stable in 36h;
Table 2 blood fat recovery capsule finger-print study on the stability result
3. blood fat recovery capsule finger-print reappearance test
Get same test sample, prepare 5 parts of need testing solutions respectively,, the results are shown in Table 3 by above-mentioned chromatographic condition sample introduction.Each finger-print and reference fingerprint be similarity＞0.90 relatively, and the result shows that the method reappearance is good.
Table 3 blood fat recovery capsule finger-print reappearance is investigated the result
Embodiment 1: the blood fat recovery capsule quality determining method
Adopt fingerprint atlas detection method:
Used instrument: Waters 600-996-717 high performance liquid chromatograph (gradient retardation time be 2.75min), Millennium
32Chromatographic work station; Chromatographic column: Apollo C
18(4.6mm*250mm, 5 μ) analytical column, TIANHE (P/N:TH0011,5 μ, C
18) guard column;
This method detects as follows:
According to high performance liquid chromatography (an appendix VI of Pharmacopoeia of the People's Republic of China D), require to measure in conjunction with finger-print;
Chromatographic condition and system suitability test are filling agent with octadecylsilane chemically bonded silica; With the acetonitrile is mobile phase A, is that Mobile phase B is carried out gradient elution with 0.05% phosphoric acid; The detection wavelength is 256nm; Column temperature is a room temperature; Flow velocity is 1.0ml/min;
The preparation of object of reference solution, precision take by weighing Lovastatin reference substance 1mg in the 5ml volumetric flask, add acetonitrile and are settled to scale, promptly;
Blood fat recovery capsule content 0.3g is got in the preparation of need testing solution, adds acetonitrile 2ml, and ultrasonic Extraction 10min filters with 0.45 μ m miillpore filter, is need testing solution;
Determination method is injected high performance liquid chromatograph with each batch need testing solution 10 μ l respectively, record 55min chromatogram.
The test sample finger-print should have good similarity with reference fingerprint, similarity＞0.90 (calculate with " the chromatographic fingerprints of Chinese materia medica similarity evaluation B of system version ", Chinese Pharmacopoeia Commission issues).
Embodiment 2: the blood fat recovery capsule quality determining method
Adopt fingerprint atlas detection method:
Used instrument: Waters 600-996-717 high performance liquid chromatograph (gradient retardation time be 2.75min), Millennium
32Chromatographic work station; Chromatographic column: Apollo C
18(4.6mm*250mm, 5 μ) analytical column, TIANHE (P/N:TH0011,5 μ, C
18) guard column;
This method detects as follows:
According to high performance liquid chromatography (an appendix VI of Pharmacopoeia of the People's Republic of China D), require to measure in conjunction with finger-print;
Chromatographic condition and system suitability test are filling agent with octadecylsilane chemically bonded silica; With the acetonitrile is mobile phase A, is that Mobile phase B is carried out gradient elution with 0.05% phosphoric acid, and the eluent gradient elution program is: the mobile phase A volume ratio rose to 84% by 25% linearity in 0～45 minute, and the Mobile phase B volume ratio drops to 16% by 75% linearity; The mobile phase A volume ratio dropped to 25% by 84% linearity in 45～55 minutes, and the Mobile phase B volume ratio rises to 75% by 16% linearity; 55～65 minutes mobile phase A volume ratios remain 25%, the Mobile phase B volume ratio remains 75%; Wherein the finger-print deadline is 55 minutes, and 55～65 minutes is the system balancing time; The detection wavelength is 256nm; Column temperature is a room temperature; Flow velocity is 1.0ml/min;
The preparation of object of reference solution, precision take by weighing Lovastatin reference substance 1mg in the 5ml volumetric flask, add acetonitrile and are settled to scale, promptly;
Blood fat recovery capsule content 0.3g is got in the preparation of need testing solution, adds acetonitrile 2ml, and ultrasonic Extraction 10min filters with 0.45 μ m miillpore filter, is need testing solution;
Determination method is injected high performance liquid chromatograph with need testing solution 10 μ l, record 55min chromatogram.The test sample finger-print should have good similarity with reference fingerprint, similarity＞0.90 (calculate with " the chromatographic fingerprints of Chinese materia medica similarity evaluation B of system version ", Chinese Pharmacopoeia Commission issues).
Embodiment 3: blood fat recovery capsule 15 peak quality determining methods
Adopt fingerprint atlas detection method:
Used instrument: Waters 600-996-717 high performance liquid chromatograph (gradient retardation time be 2.75min), Millennium
32Chromatographic work station; Chromatographic column: Apollo C
18(4.6mm*250mm, 5 μ) analytical column, TIANHE (P/N:TH0011,5 μ, C
18) guard column;
This method detects as follows:
According to high performance liquid chromatography (an appendix VI of Pharmacopoeia of the People's Republic of China D), require to measure in conjunction with finger-print;
Chromatographic condition and system suitability test are filling agent with octadecylsilane chemically bonded silica; With the acetonitrile is mobile phase A, is that Mobile phase B is carried out gradient elution with 0.05% phosphoric acid, and the eluent gradient elution program is: the mobile phase A volume ratio rose to 84% by 25% linearity in 0～45 minute, and the Mobile phase B volume ratio drops to 16% by 75% linearity; The mobile phase A volume ratio dropped to 25% by 84% linearity in 45～55 minutes, and the Mobile phase B volume ratio rises to 75% by 16% linearity; 55～65 minutes mobile phase A volume ratios remain 25%, the Mobile phase B volume ratio remains 75%; Wherein the finger-print deadline is 55 minutes, and 55～65 minutes is the system balancing time; The detection wavelength is 256nm; Column temperature is a room temperature; Flow velocity is 1.0ml/min;
The preparation of object of reference solution, precision take by weighing Lovastatin reference substance lmg in the 5ml volumetric flask, add acetonitrile and are settled to scale, promptly;
Blood fat recovery capsule content 0.3g is got in the preparation of need testing solution, adds acetonitrile 2ml, and ultrasonic Extraction 10min filters with 0.45 μ m miillpore filter, is need testing solution;
Determination method is injected high performance liquid chromatograph with need testing solution 10 μ l, record 55min chromatogram;
The test sample finger-print should have good similarity with reference fingerprint (seeing accompanying drawing 1), similarity＞0.90 (calculate with " the chromatographic fingerprints of Chinese materia medica similarity evaluation B of system version ", Chinese Pharmacopoeia Commission issues); The blood fat recovery capsule reference fingerprint has 15 total fingerprint peakses, is Lovastatin with reference to peak S;
Wherein the relative retention time of 15 total fingerprint peakses is respectively: No. 1 the peak is 0.315 ± 0.002, No. 2 the peak is 0.328 ± 0.002, No. 3 the peak is 0.378 ± 0.002, No. 4 the peak is 0.397 ± 0.006, No. 5 the peak is 0.447 ± 0.001, No. 6 the peak is 0.566 ± 0.001, No. 7 peaks are that 0.593 ± 0.001, No. 8 peaks are that 0.683 ± 0.003, No. 9 peaks are 0.784 ± 0.001, No. 10 the peak is 0.834 ± 0.001, No. 11 peaks are that 0.895 ± 0.000, No. 12 peaks are that 0.920 ± 0.000, No. 13 peaks are 0.952 ± 0.000, No. 14 peaks are that the S peak is that 1.000 ± 0.000, No. 15 peaks are 1.225 ± 0.001;
The relative peak area ratio of 15 total fingerprint peakses is respectively: No. 1 peak 0.191 ± 0.028, No. 2 peaks 0.031 ± 0.005, No. 3 peaks 0.1269 ± 0.031, No. 4 peaks 0.061 ± 0.027, No. 5 peaks 0.307 ± 0.047, No. 6 peaks 0.067 ± 0.012,0.032 ± 0.013, No. 9 peaks 0.073 ± 0.008,0.132 ± 0.021, No. 8 peaks, No. 7 peaks, No. 10 peaks 0.073 ± 0.015,0.083 ± 0.010, No. 13 peaks 0.039 ± 0.010,0.115 ± 0.030, No. 12 peaks, No. 11 peaks, No. 14 peaks are 1.000 ± 0.000, No. 15 peaks 0.119 ± 0.036, S peak.
Embodiment 4: blood fat recovery capsule 9 peak quality determining methods
Adopt fingerprint atlas detection method:
Used instrument: Waters 600-996-717 high performance liquid chromatograph (gradient retardation time be 2.75min), Millennium
32Chromatographic work station; Chromatographic column: Apoll0 C
18(4.6mm*250mm, 5 μ) analytical column, TIANHE (P/N:TH0011,5 μ, C
18) guard column;
This method detects as follows:
According to high performance liquid chromatography (an appendix VI of Pharmacopoeia of the People's Republic of China D), require to measure in conjunction with finger-print;
Chromatographic condition and system suitability test are filling agent with octadecylsilane chemically bonded silica; With the acetonitrile is mobile phase A, is that Mobile phase B is carried out gradient elution with 0.05% phosphoric acid, and the eluent gradient elution program is: the mobile phase A volume ratio rose to 84% by 25% linearity in 0～45 minute, and the Mobile phase B volume ratio drops to 16% by 75% linearity; The mobile phase A volume ratio dropped to 25% by 84% linearity in 45～55 minutes, and the Mobile phase B volume ratio rises to 75% by 16% linearity; 55～65 minutes mobile phase A volume ratios remain 25%, the Mobile phase B volume ratio remains 75%; Wherein the finger-print deadline is 55 minutes, and 55～65 minutes is the system balancing time; The detection wavelength is 256nm; Column temperature is a room temperature; Flow velocity is 1.0ml/min;
The preparation of object of reference solution, precision take by weighing Lovastatin reference substance 1mg in the 5ml volumetric flask, add acetonitrile and are settled to scale, promptly;
Blood fat recovery capsule content 0.3g is got in the preparation of need testing solution, adds acetonitrile 2ml, and ultrasonic Extraction 10min filters with 0.45 μ m miillpore filter, is need testing solution;
Determination method is injected high performance liquid chromatograph with need testing solution 10 μ l, record 55min chromatogram;
The test sample finger-print should have good similarity with reference fingerprint (seeing accompanying drawing 1), similarity＞0.90 (calculate with " the chromatographic fingerprints of Chinese materia medica similarity evaluation B of system version ", Chinese Pharmacopoeia Commission issues); The blood fat recovery capsule reference fingerprint has 9 total fingerprint peakses, is Lovastatin with reference to peak S;
The relative retention time of 9 total fingerprint peakses is respectively: No. 1 the peak is 0.315 ± 0.002, No. 2 the peak is 0.328 ± 0.002, No. 3 the peak is 0.378 ± 0.002, No. 4 the peak is 0.397 ± 0.006, No. 5 peaks are that 0.447 ± 0.001, No. 6 peaks are that 0.566 ± 0.001, No. 7 peaks are 0.593 ± 0.001, No. 14 peaks are that the S peak is that 1.000 ± 0.000, No. 15 peaks are 1.225 ± 0.001;
The relative peak area ratio of 9 total fingerprint peakses is respectively: No. 1 peak 0.191 ± 0.028, No. 2 peaks 0.031 ± 0.005, No. 3 peaks 0.1269 ± 0.031, No. 4 peaks 0.061 ± 0.027,0.067 ± 0.012, No. 7 peaks 0.132 ± 0.021,0.307 ± 0.047, No. 6 peaks, No. 5 peaks, No. 14 peaks are 1.000 ± 0.000, No. 15 peaks 0.119 ± 0.036, S peak.
Claims (7)
1, a kind of blood fat recovery capsule quality determining method is characterized in that this method comprises following finger-print quality testing step:
According to high effective liquid chromatography for measuring; Chromatographic condition and system suitability test are filling agent with octadecylsilane chemically bonded silica; With the acetonitrile is mobile phase A, is that Mobile phase B is carried out gradient elution with 0.05% phosphoric acid; This gradient elution program is: the mobile phase A volume ratio rose to 84% by 25% linearity in 0～45 minute, and the Mobile phase B volume ratio drops to 16% by 75% linearity; The mobile phase A volume ratio dropped to 25% by 84% linearity in 45～55 minutes, and the Mobile phase B volume ratio rises to 75% by 16% linearity; 55～65 minutes mobile phase A volume ratios remain 25%, the Mobile phase B volume ratio remains 75%; The detection wavelength is 256nm; Column temperature is a room temperature; Flow velocity is 1.0ml/min; The preparation of object of reference solution, precision take by weighing Lovastatin reference substance 1mg in the 5ml volumetric flask, add acetonitrile and are settled to scale, promptly; Blood fat recovery capsule content 0.3g is got in the preparation of need testing solution, adds acetonitrile 2ml, and ultrasonic Extraction 10～20min filters with 0.45 μ m miillpore filter, is need testing solution; Determination method with need testing solution 10 μ l, is injected high performance liquid chromatograph, record 55min chromatogram.
2, blood fat recovery capsule quality determining method as claimed in claim 1 is characterized in that finger-print has 15 total fingerprint peakses, is Lovastatin with reference to peak S; Wherein the relative retention time of 15 total fingerprint peakses is respectively: No. 1 the peak is 0.315 ± 0.002, No. 2 the peak is 0.328 ± 0.002, No. 3 the peak is 0.378 ± 0.002, No. 4 the peak is 0.397 ± 0.006, No. 5 the peak is 0.447 ± 0.001, No. 6 the peak is 0.566 ± 0.001, No. 7 peaks are that 0.593 ± 0.001, No. 8 peaks are that 0.683 ± 0.003, No. 9 peaks are 0.784 ± 0.001, No. 10 the peak is 0.834 ± 0.001, No. 11 peaks are that 0.895 ± 0.000, No. 12 peaks are that 0.920 ± 0.000, No. 13 peaks are 0.952 ± 0.000, No. 14 peaks are that the S peak is that 1.000 ± 0.000, No. 15 peaks are 1.225 ± 0.001;
The relative peak area ratio of 15 total fingerprint peakses is respectively: No. 1 peak 0.191 ± 0.028, No. 2 peaks 0.031 ± 0.005, No. 3 peaks 0.1269 ± 0.031, No. 4 peaks 0.061 ± 0.027, No. 5 peaks 0.307 ± 0.047, No. 6 peaks 0.067 ± 0.012,0.032 ± 0.013, No. 9 peaks 0.073 ± 0.008,0.132 ± 0.021, No. 8 peaks, No. 7 peaks, No. 10 peaks 0.073 ± 0.015,0.083 ± 0.010, No. 13 peaks 0.039 ± 0.010,0.115 ± 0.030, No. 12 peaks, No. 11 peaks, No. 14 peaks are 1.000 ± 0.000, No. 15 peaks 0.119 ± 0.036, S peak.
3, blood fat recovery capsule quality determining method as claimed in claim 2 is characterized in that finger-print has 15 total fingerprint peakses, is Lovastatin with reference to peak S; Wherein, the relative retention time of 15 total fingerprint peakses is respectively: No. 1 peak is that 0.315, No. 2 peak is 0.328, No. 3 peaks are that 0.378, No. 4 peak is that 0.3968, No. 5 peak is 0.447, No. 6 peaks are that 0.566, No. 7 peak is that 0.593, No. 8 peak is 0.683, No. 9 peaks are that 0.784, No. 10 peak is that 0.834, No. 11 peak is 0.895, No. 12 the peak is 0.920, No. 13 peaks are that 0.952, No. 14 peak is that the S peak is that 1.000, No. 15 peaks are 1.225;
The relative peak area ratio of 15 total fingerprint peakses is respectively: 0.031, No. 3 peak 0.126,0.191, No. 2 peak, No. 1 peak, 0.307, No. 6 peak 0.067,0.061, No. 5 peak, No. 4 peaks, 0.032, No. 9 peak 0.073,0.132, No. 8 peak, No. 7 peaks, No. 10 peaks 0.073,0.083, No. 13 peak 0.039,0.115, No. 12 peak, No. 11 peaks, No. 14 peaks are 1.000, No. 15 peaks 0.119, S peak.
4, blood fat recovery capsule quality determining method as claimed in claim 1 is characterized in that the blood fat recovery capsule reference fingerprint has 9 total fingerprint peakses, is Lovastatin with reference to peak S; The relative retention time of 9 total fingerprint peakses is respectively: No. 1 the peak is 0.315 ± 0.002, No. 2 the peak is 0.328 ± 0.002, No. 3 the peak is 0.378 ± 0.002, No. 4 the peak is 0.397 ± 0.006, No. 5 peaks are that 0.447 ± 0.001, No. 6 peaks are that 0.566 ± 0.001, No. 7 peaks are 0.593 ± 0.001, No. 14 peaks are that the S peak is that 1.000 ± 0.000, No. 15 peaks are 1.225 ± 0.001;
The relative peak area ratio of 9 total fingerprint peakses is respectively: No. 1 peak 0.191 ± 0.028, No. 2 peaks 0.031 ± 0.005, No. 3 peaks 0.1269 ± 0.031, No. 4 peaks 0.061 ± 0.027,0.067 ± 0.012, No. 7 peaks 0.132 ± 0.021,0.307 ± 0.047, No. 6 peaks, No. 5 peaks, No. 14 peaks are 1.000 ± 0.000, No. 15 peaks 0.119 ± 0.036, S peak.
5, blood fat recovery capsule quality determining method as claimed in claim 4 is characterized in that the blood fat recovery capsule reference fingerprint has 9 total fingerprint peakses, is Lovastatin with reference to peak S; The preferred relative retention time of 9 total fingerprint peakses is respectively: No. 1 peak is that 0.315, No. 2 peak is that 0.328, No. 3 peak is 0.378, No. 4 peaks are that 0.3968, No. 5 peak is that 0.447, No. 6 peak is 0.566, No. 7 peaks are that 0.593, No. 14 peak is that the S peak is that 1.000, No. 15 peaks are 1.225;
The relative peak area of 9 total fingerprint peakses is respectively: 0.132, No. 14 peak, 0.067, No. 7 peak, 0.307, No. 6 peak, 0.061, No. 5 peak, 0.126, No. 4 peak, 0.031, No. 3 peak, 0.191, No. 2 peak, No. 1 peak is 1.000, No. 15 peaks 0.119, S peak.
6, as described any one blood fat recovery capsule quality determining method of claim 1-5, it is characterized in that chromatographic column is an Apol lo C18 chromatographic column in the finger-print quality testing, specification is 250 * 4.6mm, 5 μ m.
7,, it is characterized in that finger-print quality testing medium wavelength detecting device is the DAD detecting device as described any one blood fat recovery capsule quality determining method of claim 1-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101458385A CN100451644C (en) | 2005-12-19 | 2006-11-17 | Method for detecting quality of blood fat recovery capsule |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510134728 | 2005-12-19 | ||
| CN200510134728.4 | 2005-12-19 | ||
| CNB2006101458385A CN100451644C (en) | 2005-12-19 | 2006-11-17 | Method for detecting quality of blood fat recovery capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1987449A CN1987449A (en) | 2007-06-27 |
| CN100451644C true CN100451644C (en) | 2009-01-14 |
Family
ID=38184328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101458385A Active CN100451644C (en) | 2005-12-19 | 2006-11-17 | Method for detecting quality of blood fat recovery capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100451644C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102384955B (en) * | 2010-09-01 | 2014-04-30 | 北京北大维信生物科技有限公司 | Method for realizing quantitative analysis on HMG-CoA reductase inhibitor in human plasma |
| CN102384954B (en) * | 2010-09-01 | 2015-03-11 | 北京北大维信生物科技有限公司 | Method for determining concentration of lovastatin and hydroxyl lovastatin acid in human plasma |
| CN102621238A (en) * | 2011-02-01 | 2012-08-01 | 北京北大维信生物科技有限公司 | Method for determining concentration of HMG-CoA reductase inhibitor |
| CN106568881A (en) * | 2015-10-12 | 2017-04-19 | 北大方正集团有限公司 | Analysis method of preparation process of statin compound |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030215932A1 (en) * | 2000-06-30 | 2003-11-20 | Parveen Kumar | Process for the isolation of lovastatin |
| CN1513451A (en) * | 2003-08-18 | 2004-07-21 | 李朝晖 | Traditional chinese medicine Monascus purpureus went using Lovastatin salt as main active and its preparation component |
-
2006
- 2006-11-17 CN CNB2006101458385A patent/CN100451644C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030215932A1 (en) * | 2000-06-30 | 2003-11-20 | Parveen Kumar | Process for the isolation of lovastatin |
| CN1513451A (en) * | 2003-08-18 | 2004-07-21 | 李朝晖 | Traditional chinese medicine Monascus purpureus went using Lovastatin salt as main active and its preparation component |
Non-Patent Citations (6)
| Title |
|---|
| 红曲中洛伐他汀总量的测定方法. 罗仁才等.卫生研究，第32卷第2期. 2003 |
| 红曲中洛伐他汀总量的测定方法. 罗仁才等.卫生研究，第32卷第2期. 2003 * |
| 高效液相色谱法测定洛伐他汀含量及有关物质. 韩明活.广东药学，第14卷第1期. 2004 |
| 高效液相色谱法测定洛伐他汀含量及有关物质. 韩明活.广东药学，第14卷第1期. 2004 * |
| 高效液相色谱法测血脂康胶囊及红曲中洛伐他汀的含量. 张小茜等.中国中药杂志，第22卷第4期. 1997 |
| 高效液相色谱法测血脂康胶囊及红曲中洛伐他汀的含量. 张小茜等.中国中药杂志，第22卷第4期. 1997 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1987449A (en) | 2007-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101850070A (en) | Quality standard and detection method for Chinese medicament Tangcao tablets | |
| CN102119961B (en) | Detection method of compound danshen dripping pills | |
| CN102091118A (en) | Quality detection method for rhodiola crenulata | |
| CN100451644C (en) | Method for detecting quality of blood fat recovery capsule | |
| CN107064322A (en) | Gallic acid and the HPLC wavelength of sanguisorbin I contents switching method in garden burnet or garden burnet class preparation are determined simultaneously | |
| CN100457125C (en) | Quality detection method for red yeast medicine | |
| CN101982189A (en) | Method for detecting salvia heart-soothing capsules | |
| CN108445125B (en) | HPLC fingerprint detection method of pain-relieving and illness-eliminating capsules | |
| CN114577574A (en) | Sanhua soup reference sample freeze-dried powder and preparation method and quality detection method thereof | |
| CN106770876A (en) | The characteristic spectrum of Radix Astragali Jianwei is set up and detection method | |
| CN111948330B (en) | Detection method of finger-print of Renzhu stomach-invigorating granules | |
| CN104655748B (en) | A kind of erigeron breviscapus granule finger-print and its method for building up and application | |
| CN114636779B (en) | Construction method of three-conversion soup reference sample freeze-dried powder fingerprint and fingerprint thereof | |
| CN110967422A (en) | Method for determining content of astragaloside in qi-tonifying and blood-nourishing tablet | |
| CN102048906A (en) | Content measurement method of abrus herb capsules | |
| CN102680593B (en) | Method for detecting medicine composition promoting qi to activate blood and dispersing blood stasis | |
| CN111487351B (en) | Method for detecting fingerprint of blood-activating pain-relieving capsule | |
| CN111929378B (en) | Method for measuring content of 6 index components of gastrodia elata in Qingda granules | |
| CN101780189A (en) | Method for controlling quality of Resina Draconis drug | |
| CN101953868B (en) | Detection method for total saponins of tribulus | |
| CN110632198B (en) | HPLC fingerprint of inflammation diminishing and cough relieving tablets and construction method and application thereof | |
| CN113655165A (en) | Fingerprint spectrum detection method of postpartum rehabilitation ointment | |
| CN114252521B (en) | Detection method of Chinese herbal medicine Chinese lobelia fingerprint | |
| CN101361839A (en) | Quality control detection method of Xuefu Zhuyu oral liquid | |
| CN110274976A (en) | A kind of rhododendron mariae Herbal HPLC Fingerprint construction method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Beijing Peking University WBL Biotech Co., Ltd. Assignor: Weixinxuezhi Sci-Tech Development Co., Ltd., Beijing Contract fulfillment period: 2008.12.1 to 2015.12.18 contract change Contract record no.: 2008110000178 Denomination of invention: Method for detecting quality of blood fat recovery capsule Granted publication date: 20090114 License type: Exclusive license Record date: 2008.12.9 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.12.1 TO 2015.12.18; CHANGE OF CONTRACT Name of requester: BEIJING WBL PEKING UNIVERSITY BIOTECH CO., LTD. Effective date: 20081209 |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING WBL PEKING UNIVERSITY BIOTECH CO., LTD. Free format text: FORMER OWNER: BEIJING WEIXINXUEZHI SCIENCE DEVELOPMENT CO., LTD. Effective date: 20090403 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090403 Address after: No. 30 Haidian South Road, Haidian District, Beijing Aerospace Precision building, 10 floor, Beijing Patentee after: Beijing Peking University WBL Biotech Co., Ltd. Address before: No. 30 Haidian South Road, Haidian District, Beijing Aerospace Precision building, 10 floor, Beijing Patentee before: Weixinxuezhi Sci-Tech Development Co., Ltd., Beijing |